Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis

S. W. Olson*, J. J. Lee, M. Poirier, D. J. Little, L. K. Prince, T. P. Baker, J. D. Edison, K. C. Abbott

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background. The subclinical pathophysiology of proliferative lupus nephritis (PLN) has not been fully elucidated. Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is associated with PLN, but prediagnostic levels have not been reported. Methods. We performed a retrospective case-control Department of Defense Serum Repository (DoDSR) study comparing MPO-ANCA levels in longitudinal prediagnostic serum samples for 23 biopsy confirmed proliferative lupus nephritis (PLN) patients to DoDSR identified age, sex, race, and age of serum matched healthy and SLE without LN disease controls. We also compared the temporal relationship of MPO-ANCA to anti-double stranded DNA antibodies (dsDNAab). Results. A greater proportion of PLN patients had prediagnostic MPO-ANCA levels above ≥3 U/mL and ≥6 U/mL compared to SLE without LN (91% versus 43%, p<0.001; 57% versus 5%, p<0.001, resp.). In subgroup analysis, the MPO-ANCA threshold of ≥3 U/mL was significant at <1 year (88% versus 39%, p=0.007) and 1-4 years (87% versus 38%, p=0.009) prior to diagnosis. Statistically significant subclinical MPO-ANCA levels (≥3 U/mL) occurred prior to statistically significant dsDNAab ≥ 3 IU/ml (89% versus 11%, p=0.003). Conclusions. Subclinical MPO-ANCA levels could distinguish future PLN from SLE without LN. MPO-ANCA manifests prior to clinical disease and subclinical dsDNAab to suggest that it may contribute directly to PLN pathogenicity.

Original languageEnglish
Article number1872846
JournalAutoimmune Diseases
StatePublished - 2017


Dive into the research topics of 'Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis'. Together they form a unique fingerprint.

Cite this